Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

NCT00856180 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Bevacizumab
DRUG: Cyclophosphamide

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]